Business
Results of TroVax® in Advanced Colorectal Cancer
Results of TroVax® in Advanced Colorectal Cancer.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 7343X Oxford Biomedica PLC 24 February 2017 \n\nOxford BioMedica Notes Encouraging Results of the Investigator Led Phase I/II clinical trial of MVA-5T4 Immunotherapy (TroVax®) and Low Dose Cyclophosphamide in Patients with Advanced Colorectal Cancer \n \n~ Both Cyclophosphamide and TroVax® independently shown to induce highly beneficial anti-tumour immune responses, resulting in significantly prolonged survival of advanced colorectal cancer patients\n \nOxford, UK - 24 February 2017: Oxford BioMedica plc (LSE:OXB) (\"Oxford BioMedica\" or \"the Group\"), a leading gene and cell therapy group, today notes the results from a Phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax®) and low dose cyclophosphamide (CPM) in patients with advanced colorectal cancer (TaCTiCC). A poster was presented by the clinical investigators in a poster session at the American Society of Clinical Oncology and Society for Imumunotherapy of Cancer (ASCO-SITC) Clinical Immuno-Oncology Symposium on 23 February 2017 in Orlando, USA.\n \nThe poster described the open-label Phase I/II clinical trial involving 53 patients with inoperable, metastatic colorectal cancer who were randomised to receive either no treatment, low dose CPM, TroVax® only or low dose CPM followed by TroVax®. The primary study endpoint was to assess increased anti-5T4 responses after treatment on day 43 and the secondary endpoints were progression free /overall survival and anti-5T4 responses over the trial period.\n \nThe study findings demonstrated that significant anti-5T4 immune responses were generated at treatment day 43. Secondary analysis revealed that both CPM and TroVax® independently induced highly beneficial anti-tumour immune responses, resulting in significant survival of end stage colorectal cancer patients, without any major toxicity. This was the first randomised study to show a benefit of immunotherapy in advanced colorectal cancer patients.\n \nCommenting on the results, John Dawson, Chief Executive Officer of Oxford BioMedica, said: \"The presentation by the Clinical Investigators of the Phase I/II TaCTiCC study at the ASCO-SITC Clinical Immuno-Oncology symposium showed the potential benefit that Oxford BioMedica's immunotherapy (TroVax®) treatment could give to patients with advanced colorectal cancer.\"\n \n...